fraudel
nevr over
- Joined
- Apr 1, 2026
- Posts
- 13
- Reputation
- 6
Comparing AIs for delaying growth plate fusion : Estradiol Suppression, Recovery, and Side Effects.
AI is abbreviated for 'Aromatase Inhibitor'.
Anastrozole and Letrozole are both non-steroidal (reversible) aromatase inhibitors, so in essence they are simply blocking the aromatase enzyme (the enzyme responsible for converting androgens into estrogens, mainly estradiol and estrone). These inhibitors can significantly suppress estradiol, which is the most potent form of estrogen, so I'll mainly dwell on estradiol production. Following discontinuation, aromatase is no longer sufficiently inhibited, so the enzymatic conversion of androgens to estrogens resumes. This is more so a return toward baseline rather than guaranteed rebound above baseline.
Half-life is also an important factor. Letrozole has a half-life of about ~50 hours (described more broadly to be between ~48-96 hours) whereas Anastrozole is around ~41–50 hours. This means that the return of estradiol tends to be less abrupt with Letrozole, as the inhibitor stays in your system for longer and its levels drop more gradually once you stop, providing its own buffer against a sudden return in estradiol production. Letrozole takes around 2–6 weeks (around ~60 days on the longer end) to reach steady state. By comparison, Anastrozole reaches steady state in around 7 days. Importantly, it clears more quickly than Letrozole. As a result, aromatase activity tends to recover faster and estradiol levels usually return faster after discontinuation. Steady state just means the inhibitor has fully built up in your system, what matters most is how quickly the aromatase inhibitor clears from your system after discontinuation.
Exemestane is yet another inhibitor that can be used, however, it is a steroidal (irreversible) inhibitor. It directly binds to and permanently inactivates the aromatase enzymes that it encounters, rather than just temporarily inhibiting them, meaning that once the medication is cleared, new enzyme synthesis is required before the body can begin producing estradiol at the same rate again. As a result, estrogen recovery is generally more gradual compared to the reversible AIs. Exemestane would be expected to produce the most gradual estrogen recovery of the three.
Keep in mind that various factors still affect how these aromatase inhibitors behave in practice, including:
While using aromatase inhibitors, most side effects stem from excessively low estradiol. Estradiol is crucial in men for bone health, libido, sexual function, and mood regulation. Excessive suppression can therefore cause joint pain or stiffness, muscle aches, fatigue, reduced libido, erectile issues, mood changes, hot flashes, sleep disruption, and decreased sense of wellbeing. Over the long term, chronically low estradiol may reduce bone mineral density, increase bone resorption, and raise the risk of osteoporosis (a condition where bone density decreases, leaving microscopic ‘holes’ in the bone structure). The severity of these side effects depends on AI dose, duration of use, individual metabolism, and how low estradiol is pushed. The key principle is to lower estradiol enough to influence the delay of growth plate fusion while maintaining sufficient levels to protect bone, joints, and overall health.
Anastrozole, Letrozole, and Exemestane all effectively suppress estradiol by approximately 85–90%, but they differ in how quickly estradiol returns after discontinuation and in their side effect profiles. Anastrozole clears faster than Letrozole, so estradiol returns more quickly, which can increase the likelihood of noticeable hormonal fluctuations, such as water retention or mood swings. Letrozole provides slightly stronger suppression with a slower post-discontinuation rise, resulting in smoother estradiol recovery and potentially milder rebound symptoms. Exemestane, as an irreversible inhibitor, produces the slowest estradiol recovery because new aromatase enzymes must be synthesised after use. This makes Exemestane the preferred option if minimising rapid post-discontinuation estradiol spikes is a priority.
All three inhibitors share similar side effects while active, primarily related to low estradiol, including joint discomfort, muscle aches, fatigue, reduced libido, mood changes, hot flashes, and sleep disruption. Long-term use can affect bone health by reducing bone mineral density and increasing the risk of osteoporosis (microscopic ‘holes’ in the bone due to low bone density). Therefore, the choice of AI should balance the degree of estradiol suppression required for delaying growth plate fusion with the need to maintain sufficient estradiol for bone, joint, and sexual health.
TLDR:
All three inhibit estradiol ~85–90% and share typical AI side effects. Careful dosing is required to protect bone, joints, and overall health while delaying growth plate fusion.
AI is abbreviated for 'Aromatase Inhibitor'.
Anastrozole and Letrozole are both non-steroidal (reversible) aromatase inhibitors, so in essence they are simply blocking the aromatase enzyme (the enzyme responsible for converting androgens into estrogens, mainly estradiol and estrone). These inhibitors can significantly suppress estradiol, which is the most potent form of estrogen, so I'll mainly dwell on estradiol production. Following discontinuation, aromatase is no longer sufficiently inhibited, so the enzymatic conversion of androgens to estrogens resumes. This is more so a return toward baseline rather than guaranteed rebound above baseline.
Half-life is also an important factor. Letrozole has a half-life of about ~50 hours (described more broadly to be between ~48-96 hours) whereas Anastrozole is around ~41–50 hours. This means that the return of estradiol tends to be less abrupt with Letrozole, as the inhibitor stays in your system for longer and its levels drop more gradually once you stop, providing its own buffer against a sudden return in estradiol production. Letrozole takes around 2–6 weeks (around ~60 days on the longer end) to reach steady state. By comparison, Anastrozole reaches steady state in around 7 days. Importantly, it clears more quickly than Letrozole. As a result, aromatase activity tends to recover faster and estradiol levels usually return faster after discontinuation. Steady state just means the inhibitor has fully built up in your system, what matters most is how quickly the aromatase inhibitor clears from your system after discontinuation.
Exemestane is yet another inhibitor that can be used, however, it is a steroidal (irreversible) inhibitor. It directly binds to and permanently inactivates the aromatase enzymes that it encounters, rather than just temporarily inhibiting them, meaning that once the medication is cleared, new enzyme synthesis is required before the body can begin producing estradiol at the same rate again. As a result, estrogen recovery is generally more gradual compared to the reversible AIs. Exemestane would be expected to produce the most gradual estrogen recovery of the three.
Keep in mind that various factors still affect how these aromatase inhibitors behave in practice, including:
- Dose used (how much AI is taken)
- Degree of aromatase suppression achieved (how effectively the AI is reducing the activity of the aromatase enzyme)
- Steady-state concentration (point at which the amount of AI in your body stabilises during regular dosing)
- Individual metabolism (how quickly the body processes and clears the AI, which influences its effectiveness and recovery of estradiol)
- Substrate load (how much androgen is available to aromatize)
- Feedback changes (hormonal adjustments the body makes in response to low estradiol)
While using aromatase inhibitors, most side effects stem from excessively low estradiol. Estradiol is crucial in men for bone health, libido, sexual function, and mood regulation. Excessive suppression can therefore cause joint pain or stiffness, muscle aches, fatigue, reduced libido, erectile issues, mood changes, hot flashes, sleep disruption, and decreased sense of wellbeing. Over the long term, chronically low estradiol may reduce bone mineral density, increase bone resorption, and raise the risk of osteoporosis (a condition where bone density decreases, leaving microscopic ‘holes’ in the bone structure). The severity of these side effects depends on AI dose, duration of use, individual metabolism, and how low estradiol is pushed. The key principle is to lower estradiol enough to influence the delay of growth plate fusion while maintaining sufficient levels to protect bone, joints, and overall health.
Anastrozole, Letrozole, and Exemestane all effectively suppress estradiol by approximately 85–90%, but they differ in how quickly estradiol returns after discontinuation and in their side effect profiles. Anastrozole clears faster than Letrozole, so estradiol returns more quickly, which can increase the likelihood of noticeable hormonal fluctuations, such as water retention or mood swings. Letrozole provides slightly stronger suppression with a slower post-discontinuation rise, resulting in smoother estradiol recovery and potentially milder rebound symptoms. Exemestane, as an irreversible inhibitor, produces the slowest estradiol recovery because new aromatase enzymes must be synthesised after use. This makes Exemestane the preferred option if minimising rapid post-discontinuation estradiol spikes is a priority.
All three inhibitors share similar side effects while active, primarily related to low estradiol, including joint discomfort, muscle aches, fatigue, reduced libido, mood changes, hot flashes, and sleep disruption. Long-term use can affect bone health by reducing bone mineral density and increasing the risk of osteoporosis (microscopic ‘holes’ in the bone due to low bone density). Therefore, the choice of AI should balance the degree of estradiol suppression required for delaying growth plate fusion with the need to maintain sufficient estradiol for bone, joint, and sexual health.
TLDR:
- Anastrozole: fast suppression, faster estradiol return, higher risk of post-discontinuation fluctuations (temporary hormonal imbalances)
- Letrozole: strong suppression, slower estradiol return, smoother recovery.
- Exemestane: irreversible inhibition so synthesis is required for estradiol production to resume, slowest estradiol recovery, lowest rebound risk.
All three inhibit estradiol ~85–90% and share typical AI side effects. Careful dosing is required to protect bone, joints, and overall health while delaying growth plate fusion.
